Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis
| Autor: | Mark Pian, T. D. Murphy, David M. Orenstein, Christopher M. Oermann, R. Fink, John Stevens, J. Finder, John L. Colombo, C. Ren, Michael J. Light, Ruth McBride, Jack D. Gorvoy, Carlos Milla, C. Prestige, Robert G. Castile, Karen McCoy, D. Stokes, Glenna Winnie, C. Harris, K. Voter, Geoffrey Kurland, Alan M. Jewell, Susanna A. McColley, Laurie Varlotta, Warren E. Regelmann, Peter Hiatt, Michael Bowman, Melisa A. Palacio, Drucy Borowitz, Richard S. Ginsberg, Jay D. Eisenberg, Nicole Hamblett, M. Dyson, Pedro A. Piedra, Stanley G. Cron, Paul H. Sammut, M. E. Brown |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Paramyxoviridae Cystic Fibrosis Recombinant Fusion Proteins Respiratory Syncytial Virus Infections Virus Pneumovirinae Immune system Adjuvants Immunologic Medicine Humans Mononegavirales Neutralizing antibody Child Immunization Schedule Vaccines Synthetic General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Patient Selection Public Health Environmental and Occupational Health Infant Viral Vaccines biology.organism_classification Virology Respiratory Syncytial Viruses Infectious Diseases Child Preschool Immunology biology.protein Molecular Medicine Female Seasons Antibody business |
| Zdroj: | Vaccine. 21(19-20) |
| ISSN: | 0264-410X |
| Popis: | A third generation, purified fusion protein (PFP-3) vaccine was developed to prevent severe respiratory syncytial virus (RSV) disease in high-risk groups. A phase II, multi-center, adjuvant-controlled trial was performed in RSV seropositive children with cystic fibrosis (CF); 151 received the adjuvant-control and 143 received the vaccine. Details of the vaccine-induced immune response are presented. At enrollment, RSV-specific, serum antibodies were comparable between both groups. A highly sensitive and specific serum antibody vaccine profile was established for the PFP-3 vaccine. At post-vaccination and end-of-study, RSV-specific, neutralizing antibody (Nt Ab) and binding antibody (Bd Ab) to the fusion (F) protein were significantly higher in PFP-3 vaccinees. After 28 days post-vaccination, Nt Ab and Bd Ab to F protein titers declined slowly at rates of 0.23 and 0.37 log2 per month, respectively. The PFP-3 vaccine-induced a robust immune response that lasted throughout the RSV season. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect